Women of childbearing potential (WOCBP) and males who are sexually active with WOCBP must use an accepted and effective method of contraception or abstain from sexual intercourse for at least one week prior to the start of treatment, and continue for  months after the last dose of protocol treatment for women of childbearing potential and  months after the last dose of protocol treatment for males who are sexually active with WOCBP
Women of childbearing potential (WOCBP) and males who are sexually active with WOCBP must use an accepted and effective method of contraception or abstain from sexual intercourse for at least one week prior to the start of treatment, and continue for  months after the last dose of protocol treatment for women of childbearing potential and  months after the last dose of protocol treatment for males who are sexually active with WOCBP
Women of childbearing potential (WOCBP) and sexually active males must use an accepted and effective method of contraception while receiving protocol treatment or abstain from sexual intercourse for the duration of their participation in the study; WOCBP must use birth control for two weeks prior to the start of the treatment and continue for  weeks after the last dose of the study drug; sexually active male patients must use effective contraception from day  of treatment and continue for  months after the last dose of the study drug
Sexually active women of childbearing potential and sexually active men must practice adequate contraception during therapy and for  months after protocol treatment completion
In sexually active patients (women of childbearing potential and males), willingness to use  effective methods of contraception, of which  must be a physical barrier method (condom, diaphragm, or cervical/vault cap) until  months after the last dose of FPA. Other effective forms of contraception include:
Sexually active patients of childbearing potential must agree to use effective contraception
Sexually active females of childbearing potential and sexually active males with partners of reproductive potential: unwilling or unable to use appropriate contraception from screening until at least  months after last administration of study treatment.
Sexually active patients and their partners agree to use an accepted method of contraception during the course of the study (Appendix C:Guidelines Regarding Women of Childbearing Potential).
Sexually active patients of childbearing potential must be willing to use effective contraception during therapy and for at least  month after treatment is completed
Sexually active males unwilling to practice contraception during the study and  months beyond
Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment
Patients must not be pregnant or lactating as chemotherapy is thought to present substantial risk to the fetus/infant; women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment and negative serum or urine ?-hCG\r\npregnancy test at screening for patients of childbearing potential
Women of childbearing potential and sexually active males must commit to the use of effective contraception while on study
Females of childbearing potential, and males, must be willing to use an effective method of contraception
Sexually active female and male subjects must be willing to use an effective method to avoid pregnancies.
PART  GROUP  INCLUSION CRITERIA: Males and females who are sexually active must agree to use effective contraception during and for three months after treatment
PART  GROUP A INCLUSION CRITERIA: Males and females who are sexually active must agree to use effective contraception during and for three months after treatment
PART  GROUP  INCLUSION CRITERIA: Males and females who are sexually active must agree to use effective contraception during and for three months after treatment
Females >  years of age or who have achieved menarche must have a negative pregnancy test within  weeks of starting treatment (urine or serum) to be eligible and if sexually active must also agree to use contraception; male sexually active patients must agree to use an effective method of contraception
Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment
Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment
Sexually active patients of childbearing potential must agree to use effective contraception
Agreement by females of childbearing potential and sexually active males to use an effective method of contraception while participating in this study; women of childbearing potential must have a negative pregnancy test <  weeks prior to registration
Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment
Sexually active males and females of childbearing potential must agree to use a form of contraception considered effective and medically acceptable by the investigator
Sexually active females of childbearing potential and sexually active males with partners of reproductive potential: unwilling or unable to use appropriate contraception from screening until at least  months after last administration of study treatment.
Women of childbearing potential and sexually active males should use effective contraception while on study
Women of childbearing potential and sexually active males should use effective contraception while on study
Women of childbearing potential and sexually active males must commit to the use of adequate contraception from the study start to one year after the last dose of study treatment
REGISTRATION TO TREATMENT (STEP ): Women of childbearing potential and sexually active males must use an accepted and effective method of contraception or to abstain from sex from time of registration, while on study treatment, and continue for  days after the last dose of study treatment
REGISTRATION TO TREATMENT (STEP ): Women of childbearing potential and sexually active males must use an accepted and effective method of contraception or to abstain from sex from time of registration, while on study treatment, and continue for  days after the last dose of study treatment
ENROLLMENT: Sexually active males and females of childbearing potential must agree to use a form of contraception considered effective and medically acceptable by the investigator. (Non-childbearing potential defined as pre-menarche, greater than one year post-menopausal or surgically sterilized).
Females of childbearing potential, and males, must be willing to use an effective method of contraception
If sexually active, willingness to use effective barrier or medical contraception
Sexually active men with partners of women of childbearing potential must agree to practice effective methods of contraception during the study and for  months after the last treatment
Women of childbearing potential and sexually active males must use an accepted and\n             effective method of contraception throughout the study and for  weeks after\n             completion of the study.
Sexually active patients of childbearing potential must agree to use an effective method of contraception during the study and for at least  months after the completion of bevacizumab therapy
Women of childbearing potential and sexually active males must use contraception while on study
Subjects who are women of childbearing potential and sexually active males must be willing to use effective contraception while on study
ECOG performance status of  to   In sexually-active patients, willingness to use  effective methods of contraception
Females of childbearing potential and nonsterilized males who are sexually active must use effective methods of contraception
Women of childbearing potential and sexually active males must agree to practice abstinence or use an accepted and effective method of contraception
Males (if sexually active with a FCBP) must
Patients who are sexually active must use a reliable form of contraception while on study and for  weeks after the last immunization
Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment
Sexually active patients of childbearing potential must agree to use effective contraception
Females of childbearing potential and sexually active males must agree to use an accepted and effective method of contraception while on study
Females of childbearing potential, and males, must be willing to use an effective method of contraception
Patients who are sexually active must use a reliable form of contraception while on study and for  weeks after the last immunization
Sexually active patients of reproductive potential must be willing to use an effective method of contraception
Males and females of childbearing potential must be able and willing to use an effective contraceptive method during treatment and for three months after completing treatment
Women of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study and for  days following the last dose;
Women of childbearing potential and sexually active men enrolled in the study must agree to practice effective contraception method during treatment and for three months after completing treatment
Female patients of childbearing potential who are sexually active and unwilling to use a medically acceptable method of contraception during the trial and for  months after the last administration of BI 
Patients of childbearing potential who are sexually active and unwilling to use a highly effective method of contraception
Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment
Sexually active patients of reproductive potential must be willing to use an effective method of contraception
Sexually active women of childbearing potential must use effective birth control during the trial and for at least two months following the trial, and sexually active men must be willing to avoid fathering a new child while receiving therapy
Sexually active females of childbearing potential and sexually active males with partners of reproductive potential: unwilling or unable to use appropriate contraception from screening until at least  days after last administration of study treatment
Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment
Sexually active males not committing to birth control during the course of the study (except if their partner is not of childbearing potential)
Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment
Females who are sexually active without use of effective contraception
Sexually active patients of childbearing potential not using a reliable contraceptive method
Sexually active patients of childbearing potential must agree to use an effective method of contraception during the study and for at least  months after the completion of bevacizumab therapy
